MET‐targeted therapies, which include HGF‐neutralizing antibodies, MET‐down‐regulating antibodies, and MET tyrosine kinase inhibitors, are currently being exploited as powerful strategies to treat tumours (Comoglio, Trusolino, & Boccaccio, 2018). This evidence concerns the gene MET and neoplasm.